Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Releases

Year

Sep 07, 2022

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 09, 2022

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Aug 03, 2022

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

Aug 01, 2022

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal

Jul 26, 2022

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

Jul 05, 2022

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

Jun 07, 2022

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

May 20, 2022

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

May 09, 2022

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 05, 2022

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2022 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap